Neurogene AAQS
The The AAQS of Neurogene (NGNE) as of Oct 20, 2026 is 4. In the previous year, The AAQS was 4.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
4
YoY
0.00%
Last updated:
Neurogene has a current AAQS of 4.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Neurogene in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Neurogene in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
The Neurogene AAQS history
3 Years
10 Years
25 Years
Max
AAQS
Date
AAQS
Jan 1, 2018
4.00 USD
Jan 1, 2019
4.00 USD
Jan 1, 2020
4.00 USD
Jan 1, 2021
4.00 USD
Jan 1, 2022
4.00 USD
Jan 1, 2023
4.00 USD
Jan 1, 2024
4.00 USD
Jan 1, 2025
4.00 USD
| YEAR | AAQS | YoY |
|---|---|---|
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Neurogene Stock analysis
What does Neurogene do? Neurogene Inc, headquartered in New York City, operates in the Health Care sector within the Biotechnology industry. The company, listed on March 7, 2014, focuses on developing genetic medicines for rare neurological diseases. Its proprietary EXACT platform enables precise transgene regulation for therapies like NGN-401, an AAV9-based treatment for Rett syndrome, and NGN-101 for CLN5 Batten disease, aiming to overcome limitations of conventional gene therapy. Neurogene is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Neurogene stock
The AAQS of Neurogene is 4 in 2025.
On Eulerpool you can find the complete historical development of The AAQS Neurogene since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Neurogene
All Key Metrics — Neurogene
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth